Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Endocrinological Investigation
Published in: Journal of Endocrinological Investigation 8/2019

01-08-2019 | Mood Disorders | Original Article

Differences in the cluster of depressive symptoms between subjects with type 2 diabetes and individuals with a major depressive disorder and without diabetes

Authors: J. Nicolau, R. Simó, C. Conchillo, P. Sanchís, J. Blanco, J. M. Romerosa, R. Fortuny, A. Bonet, L. Masmiquel

Published in: Journal of Endocrinological Investigation | Issue 8/2019

Login to get access

Abstract

Background

Depressive disorder encompasses a wide spectrum of somatic and psychological symptoms. It is not known whether there are differences regarding the cluster of depressive symptomatology between subjects with depression with and without T2DM.

Purpose

To explore whether the cluster of depression that prevails among depressive subjects with T2DM differs from individuals with depression, but without T2DM.

Methods

87 T2DM patients with a pathological Beck Depression Inventory test (BDI) were compared with 50 age- and gender-matched individuals with a major depressive disorder. All 21 items expressed in the BDI were compared between the two groups.

Results

The score obtained after administering the BDI was comparable between patients with T2DM and significant depressive symptoms and the control group (18.8 ± 2.7 vs 18.9 ± 3.4; p = 0.9). Subjects with T2DM had higher scores compared with the control group in the following items: sadness (1.4 ± 0.9 vs 0.9 ± 0.9; p = 0.011), difficulty in concentration (1.3 ± 0.8 vs 0.8 ± 0.8; p = 0.01), indecisiveness (1.1 ± 0.8 vs 0.5 ± 0.9; p = 0.012), worries about their health (1.3 ± 0.9 vs 0.6 ± 0.9; p < 0.0001), fatigue (1.2 ± 0.6 vs 0.8 ± 0.7; p = 0.003) and loss of sexual appetite (2.7 ± 0.6 vs 1.2 ± 1.3; p = 0.0001). Suicidal ideation was significantly lower among subjects with T2DM compared with the control group (0.1 ± 0.3 vs 0.6 ± 0.8; p = 0.0001).

Conclusions

Subjects with T2DM and a positive screening for depression presented a different cluster of depression compared with depressed subjects without T2DM, with a predominance of somatic–biological depressive symptoms rather than psychological–cognitive cluster and negative emotions, such as suicidal ideation.
Literature
1.
2.
Moussavi S, Chatterji S, Verdes E, Tandon A, Patel V, Ustun B (2007) Depression, chronic diseases, and decrements in health: results from the World Health Surveys. Lancet 370:851–858CrossRefPubMed
3.
Roy T, Lloyd CE (2012) Epidemiology of depression and diabetes: a systematic review. J Affect Disord 142(Suppl):S8–S21CrossRefPubMed
4.
Pouwer F, Geelhoed-Duijvestijn PH, Tack CJ et al (2010) Prevalence of comorbid depression is high in out-patients with type 1 or type 2 diabetes mellitus. Results from three out-patient clinics in the Netherlands. Diabet Med 27:217–224CrossRefPubMed
5.
Li C, Ford ES, Strine TW et al (2008) Prevalence of depression among US adults with diabetes: findings from the 2006 behavioural risk factor surveillance system. Diabetes Care 31:105–107CrossRefPubMed
6.
Lloyd CE, Roy T, Nouwen A et al (2012) Epidemiology of depression in diabetes: international and cross-cultural issues. J Affect Disord 142(Suppl):S22–S29CrossRefPubMed
7.
Castro-Costa E, Dewey M, Stewart R et al (2007) Prevalence of depressive symptoms and syndromes in later life in ten European countries: the SHARE study. Br J Psychiatry 191:393–401CrossRefPubMed
8.
Copeland JR, Beekman AT, Braam AW et al (2004) Depression among older people in Europe: the EURODEP studies. World Psychiatry 3:45–49PubMedPubMedCentral
9.
Nicolau J, Simó R, Sanchís P, Ayala L, Fortuny R, Rivera R, Masmiquel L (2016) Prevalence and clínical correlators of undiagnosed significant depressive symptoms among individuals with type 2 diabetes in a Mediterranean population. Exp Clin Endocrinol Diabetes 124:1–7CrossRef
10.
Finkelstein EA, Bray JW, Chen H et al (2003) Prevalence and costs of major depression among elderly claimants with diabetes. Diabetes Care 26:415–420CrossRefPubMed
11.
Egede LE, Zheng D, Simpson K (2002) Comorbid depression is associated with increased health care use and expenditures in individuals with diabetes. Diabetes Care 25:464–470CrossRefPubMed
12.
de Groot M, Anderson R, Freedland KE et al (2001) Association of depression and diabetes complications: a meta-analysis. Psychosom Med 63:619–630CrossRefPubMed
13.
Katon WJ, Young BA, Russo J et al (2013) Association of depression with increased risk of severe hypoglycaemic episodes in patients with diabetes. Ann Fam Med 11:245–250CrossRefPubMedPubMedCentral
14.
Duru NS, Civilibal M, Elevli M (2016) Quality of life and psychological screening in children with type 1 diabetes and their mothers. Exp Clin Endocrinol Diabetes 124:105–110PubMed
15.
Richardson LK, Egede LE, Mueller M et al (2008) Longitudinal effects of depression on glycemic control in veterans with type 2 diabetes. Gen Hosp Psychiatry 30:509–514CrossRefPubMed
16.
Aikens JE, Perkins DW, Lipton B et al (2009) Longitudinal analysis of depressive symptoms and glycemic control in type 2 diabetes. Diabetes Care 32:1177–1181CrossRefPubMedPubMedCentral
17.
de Groot M, Jacobson AM, Samson JA et al (1999) Glycemic control and major depression in patients with type 1 and type 2 diabetes mellitus. J Psychosom Res 46:425–435CrossRefPubMed
18.
Lustman PJ, Clouse RE, Nix BD et al (2006) Sertraline for prevention of depression recurrence in diabetes mellitus: a randomized, double-blind, placebo-controlled trial. Arch Gen Psychiatry 63:521–529CrossRefPubMed
19.
Lustman PJ, Freedland KE, Griffith LS et al (2000) Fluoxetine for depression in diabetes: a randomized double-blind placebo-controlled trial. Diabetes Care 23:618–623CrossRefPubMed
20.
Amsterdam JD, Shults J, Rutherford N et al (2006) Safety and efficacy of s-citalopram in patients with co-morbid major depression and diabetes mellitus. Neuropsychobiology 54:208–214CrossRefPubMed
21.
Paile-Hyvaärinen M, Wahlbeck K, Eriksson JG (2007) Quality of life and metabolic status in mildly depressed patients with type 2 diabetes treated with paroxetine: a double-blind randomised placebo controlled 6-month trial. BMC Fam Pract 8:34–37CrossRef
22.
Ghaeli P, Shahsavand E, Mesbahi M et al (2004) Comparing the effects of 8-week treatment with fluoxetine and imipramine on fasting blood glucose of patients with major depressive disorder. Clin Psychopharmacol 24:386–388CrossRef
23.
Nicolau J, Rivera R, Francés C et al (2013) Treatment of depression in type 2 diabetic patients: effects on depressive symptoms, quality of life and metabolic control. Diabetes Res Clin Pract 101:148–152CrossRefPubMed
24.
American Psychiatric Association (2013) Diagnostic and statistical manual of mental disorders DSM-V, 5th edn. American Psychiatric Publishing, ArlingtonCrossRef
25.
26.
de Jonge P (2011) Depression deconstruction lessons from psychosomatic research. J Psychosom Res 71:59–60CrossRefPubMed
27.
Beck AT, Steer RA, Brown GA (1996) Beck Depression Inventory-II (BDI-II). Manual. Pearson, Oxford
28.
Lustman PJ, Clouse RE, Griffith LS et al (1997) Screening for depression in diabetes using the Beck Depression Inventory. Psychosom Med 59:24–31CrossRefPubMed
29.
30.
Gomis R, Artola S, Conthe P, Vidal J, Casamor R, Font B, Grupo de Estudio OBEDIA (2014) Prevalencia de diabetes mellitus tipo 2 en pacientes ambulatorios con sobrepeso u obesidad en España. Estudio OBEDIA. Med Clin 142:485–492CrossRef
31.
32.
Jantaratnotai N, Mosikanon K, Lee Y, McIntyre RS (2017) The interface of depression and obesity. Obes Res Clin Pract 11:1–10CrossRefPubMed
33.
Han SJ, Kim HJ, Choi YJ, Lee KW, Kim DJ (2013) Increased risk of suicidal ideation in Korean adults with both diabetes and depression. Diabetes Res Clin Pract 101:e14CrossRefPubMed
34.
ten Have M, de Graaf R, van Dorsselaer S, Verdurmen J, Van Land H, Vollebergh W (2009) Incidence and course of suicidal ideation and suicide attempts in the general population. Can J Psychiatry 54:824–833CrossRefPubMed
35.
Handley TE, Inder KJ, Kay Lambkin FJ, Stain HJ, Fitzgeranld M, Lewin TJ (2012) Contributors to suicidality in rural communities: beyond the effects of depression. BMC Psychiatry 12:105CrossRefPubMedPubMedCentral
36.
Ceretta LB, Reus GZ, Abelaira HM, Jornada LK, Schwalm MT, Hoepers NJ (2012) Increased prevalence of mood disorders and suicidal ideation in type 2 diabetic patients. Acta Diabetol 49(Suppl 1):S227–S234CrossRefPubMed
37.
Wang B, An X, Shi X, Zhang J (2017) Suicide risk in patients with diabetes: a systematic review and meta-analysis. EJE 177:R169–R181CrossRef
38.
De Ridder D, Geenen R, Kuijer R, van Middendorp H (2008) Psychological adjustment to chronic disease. Lancet 372:246–255CrossRefPubMed
39.
Ehrmann D, Schmitt A, Reimer A, Haak T, Kulzer B, Hermanns N (2017) The affective and somatic side of depression: subtypes of depressive symptoms show diametrically opposed associations with glycemic control in people with type 1 diabetes. Acta Diabetol 54:749–756CrossRefPubMed
Metadata
Title
Differences in the cluster of depressive symptoms between subjects with type 2 diabetes and individuals with a major depressive disorder and without diabetes
Authors
J. Nicolau
R. Simó
C. Conchillo
P. Sanchís
J. Blanco
J. M. Romerosa
R. Fortuny
A. Bonet
L. Masmiquel
Publication date
01-08-2019
Publisher
Springer International Publishing
Published in
Journal of Endocrinological Investigation / Issue 8/2019
Electronic ISSN: 1720-8386
DOI
https://doi.org/10.1007/s40618-019-01020-x

Other articles of this Issue 8/2019

Journal of Endocrinological Investigation 8/2019 Go to the issue

Original Article

Comparative study of testosterone and vitamin D analogue, elocalcitol, on insulin-controlled signal transduction pathway regulation in human skeletal muscle cells

Endocrinology and Art

The clinical enigma of the “Flea catcher” by Georges de La Tour: a pregnant sinner with pre-eclampsia or a hypothyroid girl?

Original Article

Association of SOD2 A16V and PON2 S311C polymorphisms with polycystic ovary syndrome in Chinese women

Original Article

Next-generation sequencing identifies novel mitochondrial variants in pituitary adenomas

Short Review

Local ablative therapy of oligoprogressive TKI-treated thyroid cancer

Original Article

Hypothalamic–pituitary–adrenal axis function in traumatic spinal cord injury-related neuropathic pain: a case–control study
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits